IBSP mediates fibroblast malignant behaviors in hypertrophic scars via interacting with SKP1.

Burns

Dermatology, The Third Affiliated Hospital of Anhui Medical University, The First People's Hospital of Hefei, Hefei, Anhui Province, China.

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aims: Hypertrophic scars (HS) are fibrotic skin conditions marked by abnormal myofibroblast proliferation and extracellular matrix accumulation. This study aimed to elucidate the functional effects and potential mechanisms of integrin-binding sialoprotein (IBSP) in hypertrophic scar fibroblasts.

Materials And Methods: IBSP protein and wnt signaling pathway were screened by transcriptomics. To characterize the role of IBSP in hypertrophic scar fibroblasts, CCK8, transwell, and WB experiments were performed.

Results: IBSP protein and wnt signaling pathway were screened by transcriptomics. Since IBSP expression was elevated in proliferative scar fibroblasts, we performed IBSP protein knockdown, revealing a significant inhibition of proliferation, migration, and invasion. Western blotting experiments demonstrated that knockdown IBSP could inhibit wnt signaling pathway and collagen formation. Subsequent investigations indicated that IBSP knockdown reduced adenosine triphosphate (ATP) production and heightened reactive oxygen species (ROS) levels in hypertrophic scar fibroblasts. In order to investigate the potential mechanism of IBSP action, mass spectrometry analysis was performed. A combination of mass spectrometry, immunoprecipitation, and immunofluorescence verified that IBSP binds to SKP1. Notably, SKP1 knockdown markedly curtailed malignant behaviors in hypertrophic scar fibroblasts, including proliferation, migration, invasion, collagen synthesis, and ATP production. Moreover, SKP1 knockdown inhibited the wnt signaling pathway while inducing ROS production.

Conclusion: Collectively, our present study suggests that IBSP promotes the malignant process in hypertrophic scar fibroblasts.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.burns.2025.107617DOI Listing

Publication Analysis

Top Keywords

hypertrophic scar
20
scar fibroblasts
20
wnt signaling
16
signaling pathway
16
ibsp
12
ibsp protein
12
malignant behaviors
8
behaviors hypertrophic
8
hypertrophic scars
8
ibsp hypertrophic
8

Similar Publications

Hypertrophic scarring (HTS) remains a critical challenge in burn care, often resulting in debilitating contractures, chronic pain, and significant psychosocial burden. While current treatment emphasizes structural repair, recent advances underscore the importance of addressing the biological drivers of fibrosis. This review synthesizes evolving strategies in burn scar prevention, highlighting tissue-engineered matrices, autologous cell therapies, and predictive molecular tools that shift care from reactive to regenerative.

View Article and Find Full Text PDF

Background: Hypertrophic scarring is a common pathological condition often associated with significant clinical symptoms. In pediatric patients, it can impair function and is difficult to treat due to the limited availability of effective treatment options.

Objective: To investigate the efficacy of pulsed dye and fractional CO laser combined with ultrasound-assisted transdermal drug delivery technology in the treatment of hypertrophic scars in pediatric patients.

View Article and Find Full Text PDF

Background: Hypertrophic and keloid scars are challenging to treat and can cause both aesthetic and functional problems. Traditional treatments such as laser therapy and corticosteroids have limited effectiveness and high recurrence rates. However, the emergence of photodynamic therapy (PDT) combined with micro-needling, especially when using methylene blue as a photosensitizer (PS) at different concentrations, offers a promising approach for scar treatment.

View Article and Find Full Text PDF

Background: Cancer-related lymphedema (CRL) is a common chronic complication following cancer treatment, characterized by impaired lymphatic drainage, interstitial fluid retention, and progressive fibrosis. Although the mechanisms of hypertrophic scar (HTS) fibrosis have been extensively investigated, the molecular drivers of fibrosis in CRL remain unclear. Identification of reliable biomarkers and novel therapeutic targets is essential for enabling early intervention.

View Article and Find Full Text PDF